Journal
JOURNAL OF NUCLEAR MEDICINE
Volume 50, Issue 6, Pages 912-919Publisher
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.109.062687
Keywords
glucose transport; radiopharmaceutical; PET; glucose clamp
Funding
- National Institute of Diabetes and Digestive and Kidney Diseases [DK14507, DK- 61994]
- Case Center for Imaging Research
- [U24 DK76169]
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK082423, U24DK076169, R37DK014507, R01DK061994, R01DK014507] Funding Source: NIH RePORTER
Ask authors/readers for more resources
We are developing a methodology for the noninvasive imaging of glucose transport in vivo with PET and F-18-labeled 6-fluoro-6-deoxy- D-glucose (F-18-6FDG), a tracer that is transported but not phosphorylated. To validate the method, we evaluated the biodistribution of F-18-6FDG to test whether it is consistent with the known properties of glucose transport, particularly with regard to insulin stimulation of glucose transport. Methods: Under glucose clamp conditions, rats were imaged at the baseline and under conditions of hyperinsulinemia. Results: The images showed that the radioactivity concentration in skeletal muscle was higher in the presence of insulin than at the baseline. We also found evidence that the metabolism of F-18-6FDG was negligible in several tissues. Conclusion: F-18-6FDG is a valid tracer that can be used in in vivo transport studies. PET studies performed under glucose clamp conditions demonstrated that the uptake of nonphosphorylated glucose transport tracer F-18-6FDG is sensitive to insulin stimulation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available